{"title":"Eliminating the Medicare Coverage Gap for Intranasal Naloxone and Nicotine Replacement Therapy","authors":"Robert A. Kleinman, Brian S. Barnett","doi":"10.1001/jama.2024.28394","DOIUrl":null,"url":null,"abstract":"This Viewpoint explores how FDA approval of intranasal naloxone and nicotine replacement therapy as over-the-counter drugs adversely affects Medicare patients because the treatments are no longer covered and urges policymakers to address this coverage gap.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/jama.2024.28394","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This Viewpoint explores how FDA approval of intranasal naloxone and nicotine replacement therapy as over-the-counter drugs adversely affects Medicare patients because the treatments are no longer covered and urges policymakers to address this coverage gap.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
